What this pack is
LOPRESSOR is the brand name in this record; metoprolol tartrate is the generic name. Read both together with the dosage form (multiple forms (oral tablets and injectable product)).
PACK CHECK · MARKET FIRST
LOPRESSORGeneric namemetoprolol tartrate
Mainland China pack-name cue倍他乐克®平片Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The label describes metoprolol as a predominantly beta-1 adrenergic blocker that slows sinus rate and affects AV-nodal conduction; at higher exposure it may also affect beta-2 receptors. This explains why pulse, blood pressure, breathing and co-medications matter, but it cannot generate an individual prescription.
Read source: United States ↗Current regulatory record · reviewed 2026-09-04More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 倍他乐克®平片
- International brand name
- LOPRESSOR
- Source-scoped market brand names
- 倍他乐克®平片 · Mainland China (company public product list)Source-scoped evidence ↗AstraZeneca China's list maps the name to metoprolol tartrate tablets 25, 50 and 100 mg. This is a name-and-strength lookup cue only and cannot be self-converted by tablet count or milligrams with U.S. LOPRESSOR metoprolol tartrate 12.5 mg.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- metoprolol tartrate
- Dosage-form class
- The current U.S. NDA 218698 product is an unscored, film-coated immediate-release metoprolol tartrate 12.5 mg tablet, supplied in bottles of 30, 60 and 1,000 tablets. It must not be combined or converted with historical 50/100 mg tablets, LOPRESSOR oral solution, LOPRESSOR HCT, injection or TOPROL-XL extended-release tablets.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:倍他乐克®平片. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · U.S. DailyMed label (SPL v3; updated 26 Jan 2026)
Metoprolol tartrate 12.5 mg per tablet; 30-tablet bottle
- Product code
- NDC 30698-460-03
- Form and route
- LOPRESSOR metoprolol tartrate 12.5 mg film-coated oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- metoprolol tartrate
- 12.5 mglabelled amount per tablet; not an individual tablet count, frequency or standard/extended-release conversion instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- pink · 5 mm round, biconvex, film-coated tablet · imprint arrowhead mark and E on one side; plain on the otherUnscored in this labelled presentation
United States label · U.S. DailyMed label (SPL v3; updated 26 Jan 2026)
Metoprolol tartrate 12.5 mg per tablet; 60-tablet bottle
- Product code
- NDC 30698-460-01
- Form and route
- LOPRESSOR metoprolol tartrate 12.5 mg film-coated oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- metoprolol tartrate
- 12.5 mglabelled amount per tablet; not an individual tablet count, frequency or standard/extended-release conversion instruction
- Package
- 60 tablets per bottle
- Labelled appearance
- pink · 5 mm round, biconvex, film-coated tablet · imprint arrowhead mark and E on one side; plain on the otherUnscored in this labelled presentation
United States label · U.S. DailyMed label (SPL v3; updated 26 Jan 2026)
Metoprolol tartrate 12.5 mg per tablet; 1000-tablet bottle
- Product code
- NDC 30698-460-10
- Form and route
- LOPRESSOR metoprolol tartrate 12.5 mg film-coated oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- metoprolol tartrate
- 12.5 mglabelled amount per tablet; not an individual tablet count, frequency or standard/extended-release conversion instruction
- Package
- 1000 tablets per bottle
- Labelled appearance
- pink · 5 mm round, biconvex, film-coated tablet · imprint arrowhead mark and E on one side; plain on the otherUnscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
Enlarged LOPRESSOR label: separate the current 12.5 mg standard tablet, historical tablets and extended release
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This reading module is limited to the current NDA 218698 12.5 mg unscored standard tablet. It does not transfer wording from historical 50/100 mg tablets, oral solution, combination, injection or extended-release products.
- The 12.5 mg figure is the labelled amount per tablet, while 30, 60 or 1,000 is the bottle count. None answers an individual's daily tablet count, splitting question or conversion to another metoprolol product.
- The label describes this tablet as unscored. That alone does not let a webpage declare that splitting is always prohibited or acceptable; use the exact pack, prescription and pharmacist/prescriber review.
- Abrupt cessation may worsen myocardial ischaemia. Do not self-stop, make up, reduce, alternate days or rotate with an extended-release tablet because of a pulse, blood-pressure value, dizziness or one missed use.
- Bradycardia, hypotension, syncope, a fall, breathing difficulty, worsening heart failure or chest pain needs timely local clinical review; use local emergency pathways for severe symptoms.
- For diabetes, fasting or vomiting, the label warns that beta blockers may mask signs of hypoglycaemia such as tachycardia. Do not rely on pulse alone to judge hypoglycaemia.
- Tell the surgical or dental team about LOPRESSOR. Do not stop it in advance based on a webpage.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-04
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 3
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg label (SPL v3; updated 26 Jan 2026) ↗Current regulatory record · reviewed 2026-09-04
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-04DailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg electronic label PDF ↗Current regulatory record · reviewed 2026-09-04
- FDA · United States · Regulatory product record or label archive · 2026-09-04FDA: label archive for historical LOPRESSOR metoprolol tartrate 50 mg/100 mg tablets, NDA 017963 (2023) ↗Historical public record · reviewed 2026-09-04
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about LOPRESSOR (metoprolol tartrate). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
LOPRESSOR is the brand in this record and metoprolol tartrate is the active-ingredient name. Check both with the dosage form (The current U.S. NDA 218698 product is an unscored, film-coated immediate-release metoprolol tartrate 12.5 mg tablet, supplied in bottles of 30, 60 and 1,000 tablets. It must not be combined or converted with historical 50/100 mg tablets, LOPRESSOR oral solution, LOPRESSOR HCT, injection or TOPROL-XL extended-release tablets.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg label (SPL v3; updated 26 Jan 2026) ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg electronic label PDF ↗Current regulatory record · reviewed 2026-09-04
- FDA: label archive for historical LOPRESSOR metoprolol tartrate 50 mg/100 mg tablets, NDA 017963 (2023) ↗Historical public record · reviewed 2026-09-04
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When TOPROL-XL / metoprolol succinate extended release is on the same list
LOPRESSOR is a standard metoprolol tartrate tablet, while TOPROL-XL is an extended-release metoprolol succinate tablet; they must be reviewed as distinct standard and extended-release tablets. A shared metoprolol name triggers a complete medicine-list review; this card does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Toprol-XL / metoprolol succinate record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Current regulatory record · reviewed 2026-09-04HOW IT WORKS · NOT A TREATMENT PLAN
How metoprolol tartrate works: mainly beta-1 blockade, but selectivity is not absolute
- Standard and extended-release tablets have different release designs. A shared active-ingredient root or similar milligrams creates no self-conversion, combination or rotation rule.
- Different NDAs, dosage forms, strengths, excipients and market labels are product-identity fields. Similar mechanisms cannot prove originator status, authenticity, sale eligibility or individual suitability.
- Pulse, blood pressure, glucose regulation, respiratory status and other heart-rate-slowing medicines all affect the risks a professional needs to review; a mechanism explanation cannot decide whether an individual should start, continue, reduce or stop treatment.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg label (SPL v3; updated 26 Jan 2026) ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg electronic label PDF ↗Current regulatory record · reviewed 2026-09-04
- FDA: approval letter for LOPRESSOR metoprolol tartrate 12.5 mg tablets, NDA 218698 (28 Aug 2025) ↗Current regulatory record · reviewed 2026-09-04
- FDA: label archive for historical LOPRESSOR metoprolol tartrate 50 mg/100 mg tablets, NDA 017963 (2023) ↗Historical public record · reviewed 2026-09-04
- AstraZeneca China: Betaloc conventional tablets (metoprolol tartrate tablets) product list ↗reviewed 2026-08-30
SOURCE-TRACEABLE ARCHIVE
LOPRESSORmetoprolol tartrate
This page includes an exact current U.S. public-label package panel for LOPRESSOR, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Legacy LOPRESSOR tablet NDA 017963 approved
FDA public review material links legacy LOPRESSOR tablets to this date and NDA 017963. This page preserves the 50/100 mg history through the 2023 label archive without treating it as the current 12.5 mg pack.
FDA: label archive for historical LOPRESSOR metoprolol tartrate 50 mg/100 mg tablets, NDA 017963 (2023) ↗Current 12.5 mg LOPRESSOR tablet NDA 218698 approved
The FDA approval letter confirms a 505(b)(2) application, with the approved use limited to the haemodynamically stable adult myocardial-infarction setting described in the letter and label.
FDA: approval letter for LOPRESSOR metoprolol tartrate 12.5 mg tablets, NDA 218698 (28 Aug 2025) ↗Current DailyMed label updated
The current label lists 12.5 mg, three NDC bottle presentations, appearance, excipients and safety sections.
DailyMed (NLM): U.S. LOPRESSOR metoprolol tartrate 12.5 mg label (SPL v3; updated 26 Jan 2026) ↗
MARKET SCOPE
Market-record boundary
Current U.S. 12.5 mg tablet
NDA 218698; three public-label bottle presentationsNDC 30698-460-03 (30), -01 (60) and -10 (1,000 tablets); directory fields are not live stock.
Legacy U.S. 50/100 mg tablets
NDA 017963 retained as a separate historical labelDo not transfer legacy indications, scoring, appearance, dosage wording or packs to the current 12.5 mg product.
Mainland China Betaloc standard tablets
Company product-list name and strength cues25, 50 and 100 mg; current approval numbers, full labels and packs still require item-by-item Chinese regulatory verification.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 倍他乐克®平片
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Why does the label say 1992 while the FDA approval letter is dated 2025?
They are not the same field. The current label heading retains Initial U.S. Approval: 1992, while the current 12.5 mg tablet is NDA 218698 with an approval letter dated 28 Aug 2025; earlier LOPRESSOR tablets also have an NDA 017963 history. Product identity requires the exact NDA, dosage form, strength, NDC and label version, not one year alone.
Can the 12.5 mg unscored tablet be split?
A webpage cannot derive an individual handling instruction from the word unscored alone. Ask a pharmacist or prescriber with the actual pack and prescription; do not substitute instructions from legacy 50/100 mg tablets, extended-release tablets or another manufacturer.
LOPRESSOR and TOPROL-XL are both metoprolol. Can they be self-switched?
No. Salt, standard/extended-release design, amount per unit, indication, pack, label and prescription all require separate checking; similar milligrams create no self-conversion, combination or rotation rule.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.